| abstract |
The present invention relates to a combination such as a combined preparation or a pharmaceutical composition each comprising a DPP-IV inhibitor or a pharmaceutically acceptable salt thereof, and an anti-obesity agent or an appetite regulating agent or a pharmaceutically acceptable salt thereof. It relates to the agent. The present invention further provides hypertension, congestive heart failure, left ventricular hypertrophy, peripheral arterial disease, diabetes, especially type 2 diabetes, diabetic retinopathy, macular degeneration, cataract, diabetic nephropathy, glomerulosclerosis, chronic renal failure. Diabetic neuropathy, X syndrome, premenstrual syndrome, coronary heart disease, angina pectoris, thrombosis, atherosclerosis, myocardial infarction, transient ischemic attack, stroke, vascular restenosis, hyperglycemia, Anti-insulinemia anti-insulinemia, hyperlipidemia, hypertriglyceridemia, insulin resistance, impaired glucose metabolism, impaired glucose tolerance, impaired fasting glucose, obesity, erectile dysfunction, skin and connective tissue disorders For the prevention, delay of progression or treatment of diseases and disorders selected from the group consisting of foot gangrene and ulcerative colitis, vascular endothelial dysfunction and reduced vascular compliance, It relates to the use of the hunt combination. |